RxDoctor Payments Data

Lasondra Bean, APRN

Family · Bowling Green, KYNPI 1710126941

Payments from drug & device makers

$5,899in general payments, 2019–2025

Across 279 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$733
  • Daiichi Sankyo Inc.$652
  • Novartis$479
  • Johnson & Johnson$408
  • AstraZeneca$397
  • Merck$338
  • plus $3K from 53 others

What the payments were for

  • Food & beverage$5,49793%
  • Education$4027%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer41$733
Daiichi Sankyo Inc.23$652
Novartis28$479
Johnson & Johnson16$408
AstraZeneca(2 entities)20$397
Merck17$338
AbbVie11$206
Amgen1$201
Gilead5$172
Bristol Myers Squibb7$160
Sanofi7$147
Ipsen Biopharmaceuticals, Inc6$118
Sobi, Inc5$105
Lilly USA, LLC5$92
Regeneron Healthcare Solutions, Inc.4$88
Blueprint Medicines Corporation4$87
Pharmacosmos Therapeutics Inc.4$83
Astellas Pharma US Inc4$80
Pharmaessentia USA Corporation4$77
E.r. Squibb & Sons, L.L.C.4$72
Incyte Corporation4$69
Stemline Therapeutics Inc.3$60
Eisai Inc.3$52
Rigel Pharmaceuticals, Inc.2$50
Coherus Oncology, Inc.2$48
Genmab U.S., Inc.2$47
EMD Serono, Inc.2$45
Beigene USA, Inc.3$45
Karyopharm Therapeutics Inc.2$43
GSK2$43
Seagen Inc.2$42
Takeda Pharmaceuticals U.S.A., Inc.2$40
Puma Biotechnology, Inc.2$40
Octapharma USA, Inc.2$39
Servier Pharmaceuticals LLC2$36
Agios Pharmaceuticals, Inc.2$36
AVEO Pharmaceuticals, Inc.2$34
Geron Corporation1$32
Genentech USA, Inc.2$32
Bayer2$30
Apellis Pharmaceuticals, Inc.1$25
Alnylam Pharmaceuticals Inc.1$23
Sumitomo Pharma America, Inc.1$23
Morphosys, US Inc.1$22
Taiho Oncology, Inc.1$22
Fennec Pharmaceuticals, Inc.1$21
Accord Healthcare, Inc.1$21
Corium, LLC1$20
Cumberland Pharmaceuticals, Inc.1$20
ADC Therapeutics America, Inc.1$16
Spectrum Pharmaceuticals Inc.1$16
Tersera Therapeutics LLC1$16
Springworks Therapeutics, Inc.1$16
Immunocore Limited1$15
Iovance Biotherapeutics, Inc.1$15
Mirati Therapeutics, Inc.1$14
Recordati_rare_diseases_inc.1$14
Pharmacyclics LLC, An Abbvie Company1$12
Array Biopharma Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,899 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$607,785
Medicare patients
282
Services billed
32,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide36$389,625
CalquenceAcalabrutinib Maleate13$137,931
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen44$1,363
Danazol12$905
Ondansetron Hcl22$869
Potassium Chloride49$823
Ondansetron OdtOndansetron35$640
Gabapentin71$513
Hydroxyurea28$459
Prochlorperazine Maleate17$318
Anastrozole21$295
Dexamethasone22$263
Promethazine Hcl15$162
Acyclovir15$146
Levothyroxine Sodium25$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$80$389,62536 claims
AstraZenecaCalquence$397$137,93113 claims
Lilly USA, LLCOlanzapine$92$1813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →